The successful production of Hematopoietic Stem and Progenitor Cells (HSPCs) from human pluripotent sources is conditioned by transgene delivery 1-5 . We describe here a dedicated and tractable one step, GMP-grade, transgene-free and stroma-free protocol to produce HSPCs from human induced pluripotent stem cells (hiPSCs). This procedure, applied to several sources of hiPSCs with equal efficiency, is based on a directed differentiation with morphogens and cytokines to generate a cell population close to nascent HSPCs or their immediate forerunners i.e., hemogenic endothelial cells 6-9 . Following engraftment into immunocompromised recipients, this cell population was proved capable of a robust myeloid, lymphoid and definitive red blood cell production in sequential recipients for at least 40 weeks. Further identification of the repopulating cells show that they express the G protein-coupled receptor APELIN (APLNR) and the homing receptor CXCR4. This demonstrates that the generation of bona fide HSPCs from hiPSCs without transgenes is possible and passes through an early endo-hematopoietic intermediate. This work opens the way to the generation of clinical grade HSPCs for the treatment of hematological diseases and holds promise for the analysis of HSPC development in the human species.
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While in standard hiPSC differentiation protocols, CD34 + CD45 + hematopoietic cells appeared from bursting Embryoid Bodies (EBs) at day 10 until day 14 1, 5, 10, 11 , here D17 EBs remained compact and spherical without burst therefore assessing a dramatic delay in differentiation ( Fig. 1a) . These culture conditions, reproducibly applied to three individual hiPSC lines, derived using different reprogramming protocols demonstrated the robustness of the method.
To determine the point of hemogenic endothelial cell (EC)/early HSPC commitment, we analyzed EBs by qRT-PCR on D3, 7, 9, 13, 15, 16 and 17 for the expression of 49 endothelialand hematopoietic-specific genes, with CD34 + cord blood (CB) HSPCs as a reference (Supplementary Table 1 ). Hierarchical clustering ( Fig. 1b , and Supplementary Fig. 1 ) revealed two main groups, one associated with CD34 + CB HSPCs and another one with D3 to D17 EBs.
The latter displayed two distinct clusters: the early EBs (D3 to D13) and the late EBs (D15 to D17). Further analysis of the qRT-PCR identified D13 as the point of EC commitment based on CD309 (VEGFR2/FLK1) mRNA expression and D16 as hemogenic endothelial commitment/EHT based on RUNX1 mRNA expression ( Fig. 1c) in keeping with developmental studies 12 . Early HSPC commitment was overt from D17 testified by the expression of ITGA2 (Integrin alpha-2), CEBPA (CCAAT enhancer binding protein alpha), the transcription factors c-MYB and SCL, this latter exhibiting a bimodal curve in keeping with its role on hemangioblast and hematopoietic commitment respectively 13 , the TPO receptor MPL (Fig 1c) . Flow cytometry indicated a decrease in CD309 (EC marker) expression from D13 to D17 and an increase of ITGA2, CKIT and MPL (early HSPC markers) expressions ( Fig. 1d ) in keeping with the qRT-PCR analysis (Fig. 1c ).
We next evaluated the endothelial and hematopoietic potential of D15 to D17 EBs using dedicated ex vivo functional tests ( Fig. 2a and Supplementary Table 2 ). D15 EBs displayed a 4 strong endothelial-forming potential since they generate endothelial colony-forming cells (CFCs) ( Fig. 2a1 ), pseudo-microtubules ( Fig. 2a2 ) and endothelial-like cells (Fig. 2a3) 14 , but lacked hematopoietic-forming capacity, being unable to generate clonogenic colonies and displaying a low frequency of long term culture-initiating cells (Supplementary Table 2 ). In contrast D17 EBs lacked endothelial potential but showed an increased hematopoietic capacity (Fig. 2a4, a5 ), confirming hematopoietic commitment within this period.
D16 cells were probed in vivo by subcutaneous transplantation in Matrigel (growth factor reduced) plug with or without human Mesenchymal Stem Cells (hMSCs) into immunocompromised Foxn1 −/− (nude) mice ( Fig. 2b) 15 . Two weeks after transplantation, both human vascular and hematopoietic differentiation was found. Human vascular structures ( Fig.   2c, d, e ), made of human von Willebrand factor + ( Fig. 2d ) and CD31 + ( Fig. 2e ) cells were detected in the graft seeded with D16 cells associated with (/) hMSCs. qRT-PCR revealed the expression of hVEGFR2, hENG (ENDOGLIN), hPECAM and hVE-CADHERIN in the D16 cells/hMSCs grafts and, as expected, in the endothelial progenitor cells/hMSCs grafts ( Supplementary Fig. 2 ). Moreover, D16 cells/hMSCs grafts also expressed the CD45 antigen and human beta, gamma and epsilon globin transcripts, while D16 cell grafts alone expressed only human epsilon globin transcript disclosing a block of maturation ( Supplementary Fig. 2 ). D16 EBs thus displayed a balanced endothelial-hematopoietic pattern in keeping with our ex vivo results.
Based on the newly-formed hematopoietic capability disclosed at D17, we transplanted 4×10 5 D17 cells intravenously into 30 sublethally irradiated (3.5 gray) 8-week-old immunocompromised mice for 20 weeks followed by a challenging secondary transplantation in similarly-treated immunocompromised recipients for 20 additional weeks and compared it 5 systematically to CD34 + CB HSPCs ( Fig. 3a, Supplementary Fig. 3a ). Hematopoietic reconstitution quantified by the surface expression of hCD45, hCD43 and hCD34 ( Fig. 3b and Supplementary Fig. 3b -l) 16 was evident in 30/30 primary recipients and quantitatively comparable to that of CD34 + CB HSPCs ( Fig. 3c and Supplementary Fig. 3b , c-e, j) with 20.3+/-2.9 % of hCD45 + cells in total mouse BM mononucleated cells, i.e., more than 200 times the threshold of 0.1% usually considered as positive for human hematopoietic engraftment in NSG mice 17 , and 12.2+/-1.5 % of hCD43 + and 7.29+/-1.0 % of hCD34 + . hCD45 + BM cells harbor several hematopoietic lineages including B and T lymphoid (hCD19 + and hCD3 + respectively) and myeloid (hCD14 + ) ( Supplementary Fig. 4a-d ) whereas hCD45 -BM cells harbor hCD235a + erythroid progenitors/precursors ( Supplementary Fig. 4a-b , e-f). Sorted hCD45 + blood cells displayed the same multilineage pattern ( Supplementary Fig. 5a ) indicating a peripheralization of the grafted cells comparable to results obtained with CD34 + CB HSPCs. Their human origin was confirmed (n=30/30) by qRT-PCR using human-specific primers ( Supplementary Fig. 4g,) . Supplementary Fig. 3l ). Human CD45 + cells represented 12.6+/-3.9 % of the mononucleated BM cells at 20 weeks ( Fig. 3d ), indicating a sustained reconstitution capacity. Multilineage engraftment was found in 30/30 secondary mice ( Fig. 3e, Supplementary Fig. 6a -e) and was comparable to the pattern obtained on secondary CD34 + CB HSPCs transplants ( Supplementary Fig. 3f -i, k and Supplementary Fig. 6 ). The 6 human CFCs cloning efficiency was 5.5+/-3.1 % in 10 4 total mouse BM cells, pointing to a robust and prolonged self-renewal potential ( Fig. 3f -h). The human origin of the engrafted cells was confirmed as above ( Supplementary Fig. 3g ).
To ensure the functionality of the grafted cells, we analyzed the ability of the human erythroid precursors from mouse BM to undergo hemoglobin switching in vivo and tested the phenotype and the functionality of T cells. Cells from both primary and secondary recipients generated human erythroid progenitors displaying high amounts of β (respectively 39.51+/-4.95% and 36.61+/-5.86%) and γ globin (respectively 57.49+/-3.95% and 61.39+/-4.86%) while ε globin was dramatically reduced to respectively 3.0+/-1.2% and 2.1+/-1.1% of total globin ( Fig. 3i ), a hallmark of definitive erythrocytes. Peripheral blood hCD3 + T cells displayed high amounts of TCRαβ ( Fig. 3j ) and low amounts of TCRγδ similar to thymic hCD3 + cells ( Supplementary Fig. 5b ) reminiscent of normal T lymphopoiesis. B and T lymphopoiesis was revealed in spleen CD45 + cells by the expression of TCRß and hCD19 and were found similar to CD34 + CB HSPCs grafts ( Supplementary Fig 5b) . Thymus hCD3 + T cells, tested on their ability to expand ex vivo, measured by CSFE-labeling, under hCD3 and hCD28 stimulation ( Fig. 3k) displayed a high expansion capacity after 5 days, thereby demonstrating T cells functionality.
To further identify the reconstituting population, we focused on APLNR related to ECs 18 and HCs from human embryonic stem cells 19 and to the homing receptor CXCR4 20, 21 .
Differentiating EBs displayed an enhanced APLNR and CXCR4 expression from D7 to D17 with the emergence of a double stained population accounting for 32.1% of the cells at D17 ( Fig   4a) . Grafting efficiency at 20 weeks was directly proportional to the number of APLNR + cells ( Fig 4b) . Moreover, only APLNR + cells reconstituted hematopoiesis after 20 weeks with 6.6+/-1.9 % hCD45 + mononucleated cells, 3.4+/-2.5 % hCD43 + and 1.1+/-0.4 % hCD34 + in 6/6 grafted 7 mice ( Fig. 4c , Supplementary Fig. 7a ) and displayed multilineage reconstitution ( Supplementary   Fig. 7b -c), Importantly, D17 APLNR + cells did not harbor any CD45 + cell indicating that reconstitution was not harbored by hCD45 + progenitors ( Supplementary Fig. 7d ). In contrast, APLNRcells failed to significantly engraft in 4/4 mice with 0.08+/-0.01 % hCD45 + cells in mouse BM (Figure 4c , Supplementary Fig 7a) . The APLNR + fraction also exhibited a homogeneous population of ENG + /TIE + /CKIT + (Fig. 4d ) described to enhance definitive hematopoiesis in mice 22 . We compared the molecular profiles of APLNR + and APLNRcells to that of D15 and D17 EBs, to hiPSCs and to control CD34 + CB HSPCs through the expression of the set of 49 genes (Supplementary Table 3 ). Principal component analysis (PCA) of the 49 mRNAs as variables and the six cell populations as observations revealed that the first component likely corresponded to the factor "hematopoietic differentiation" (44.9% of the variance) ( Fig. 4e ). Aiming to reveal the traits involved in the grafting potential, we compared by PCA the APLNR + , D17 and CB HSPC populations to the APLNRand hiPSC populations. The third component that accounted for 19.23% of the variance segregated two groups differing by their grafting potential ( Fig. 4f) . A statistical SAM test which measures the strength of the relationship between gene expression and a response variable pointed out 8 genes (FDR<10%) significantly up-regulated in the group unable to graft, among them endothelial genes as TEK, PECAM, and KDR ( Fig. 4g ).
Collectively, we show that the generation of long-term multipotent HSPCs supporting hematopoietic reconstitution and self-renewal in vivo, passes through an early differentiated cell expressing APLNR more likely an endothelial cell undergoing EHT or a newly formed HSPC.
Since this study has been performed under GMP-grade conditions, it may be envisioned that pluripotent stem cells may become a prioritized source of cells for HSPC transplantation. (f) PCA with the set of 49 mRNAs as variables and the populations endowed or not with grafting potential. The PC3 dimension which accounts for 19.23% of the variance segregates the two groups.
Figure Legends
(g) Heat map of the genes permitting the segregation of the two groups in (f).
Materials and Methods: hiPSC amplification
The study was conducted using three different hiPSC lines: the FD136-25 (skin primary 
Colony assays
At the indicated times, 1x10 5 dissociated EBs or 3x10 4 cells from xenotransplanted recipient BM were plated into 3 mL of complete methylcellulose medium in the presence of SCF, IL-3, EPO and GM-CSF (PeproTech, Neuilly-sur-Seine, France). As G-CSF also stimulates mouse progenitors, it was replaced by granulocyte-macrophage colony-stimulating factor (GM-CSF). 12 Aliquots (1 mL) of the mix were distributed into one 30 mm dish twice and maintained in a humidified chamber for 14 days. Colony-forming Cells (CFC) were scored on day 14.
Long-term culture-initiating cell assays
Long-term culture-initiating cell (LTC-IC) assays were performed as described previously (35), 15 -100,000 cells/well on day 17 for the EBs and on day 0 for the control CD34+. Absolute LTC-IC counts corresponded to the cell concentrations, yielding 37% negative wells using Poisson statistics.
Pseudo-microtubules and EPC-like cells
For Pseudo-microtubules formation, cells were transferred onto growth factor reduced Matrigel (Corning) and culture in EGM2 medium (Lonza).
For EPC-like cells generation, cells were first plated on gelatin and cultured in EBM2 (Lonza) and split several times, after the first passaged the gelatin was no longer mandatory.
Flow cytometry
Staining of BM cells or dissociated EBs was performed with 2x10 5 cells in 100 µL staining buffer (PBS containing 2% FBS) with 5:100 dilution of each antibody, for 20 min at room temperature in the dark. Data acquisition was performed on a Becton Dickinson Canto II cytometer. 13 In vivo analyses of angiogenesis potential In vivo assessment of the endothelial and hematopoietic potentials were probed on 9 nude mice.
1.750 10 6 D16 single cells or hEPCs and 1.750 10 6 hMSCs were mixed with 100µl of Matrigel phenol red free and growth factor reduced (Corning) and subcutaneously injected into the back of nude mice (two different plugs/ mouse). The controls were performed similarly but with 3.5 10 6 hMSCs or D16 single cells or hEPCs; for each condition n=3. Two weeks later, mice were sacrificed, the matrigel plug dissected out and cut into two parts. One part was processed for paraffin sectioning. Sections were deparaffinized, hydrated and stained whether with Masson's trichrome, a three-color protocol comprising nuclear staining with hematoxylin, cytoplasmic staining with acid fuchsin/xykidine ponceau and collagen staining with Light Green SF (all from VWR); or whether with an anti human Von Willebrand factor antibody (Dako), staining was developed with histogreen substrate (Abcys) and counterstained with Fast nuclear red (DakoCytomation), dehydrated and mounted, or wether with hCD31 (R&D system) as primary antibody and donkey anti-rabbit Cy3 (Jackson ImmunoResearch) as secondary antibody and DAPI and mounted with fluoromount G. 14 Cells were stained with the antibody hAPJ-APC clone 72133 (R&D systems) as described above.
Sorting of APLNR positive cells
Sorting was carried out on a Moflo ASTRIOS Beckman Coulter apparatus and the purity was 98.1% APLNR + cells. For the engraftment potential of the D17 cells on the three different hiPSC lines:
Mouse transplantation
86 NSG mice were used as followed: 30 primary recipients, 30 secondary recipients and 26 as control.
48 NOD-SCID mice were used as followed: 20 primary recipients and 16 secondary recipients, 3 tertiary recipients and 9 as control.
For the engraftment potential of APLNR + and APLNRpopulation: 10 NOD-SCID mice were used and 3 NOD-SCID as control. 15 
Assessment of human cell engraftment
Mice were sacrificed at week 12, 18 or 20. Femurs, tibias, liver, spleen and thymus were removed. Single cell suspensions were prepared by standard flushing and aliquots containing 1x10 6 cells were stained in a total volume of 200µL staining buffer.
Samples were stained for engraftment assessment with the following markers: hCD45 clone J33, hCD43 clone DFT1, hCD34 clone 581 (Beckman Coulter) and hCD45 clone 5B1, mCD45 clone
30F11 (Miltenyi)
The BM of three mice were pooled to allow hCD45 microbead enrichment (Miltenyi), the multilineage was assessed using the following human markers : hCD3 clone UCHT1, hCD4 The blood samples of three mice were pooled to allow hCD45 microbead sorting (Miltenyi). The multilineage potential was assessed using the following human markers : hCD3 clone UCHT1, hCD4 clone 13B8.2, hCD8 clone B9.11, hCD14 clone RMO52, hCD15 clone 80H5, hCD11B
Bear1, hCD19 clone J3-119, hCD20 clone B9E9, hIGM clone SA-DA4 (all from Beckman
Coulter antibodies, Brea, USA).
Non-injected mouse BM was used as a control for non-specific staining.
Compensation was performed by the FMO method with anti-mouse Ig and data were acquired on a BD Canto II cytometer. 16 The presence of TCR αβ and TCR γδ in peripheral blood was assessed by flow cytometry using the following human markers : hCD3 clone UCHT1 (positive gating), TCR αβ clone IP26A and TCR γδ clone IMMU510 (all from Beckman Coulter antibodies, Brea, USA).
T-cell maturity and functionality assay
Thymus and spleen cells were isolated, CFSE labelled and seeded in cell culture media complemented or not with hCD3 and hCD28 (Beckman Coulter both 1µg/ml). After 5 days, cells were harvested and stained with anti-hCD3 clone UCHT1 and analyzed on a BD Canto II cytometer. FlowJo analysis software was used to gate on CD3 + T-cells and generate the overlaid histogram plots.
Assessment of the APLNR cell safety
Three sub-lethally irradiated NOD/SCID mice were subcutaneously injected each with 3 million APLNR positive cells. No teratoma was found after 2 months follow-up according to FDA guidelines.
In addition, no tumor was macroscopically detected in any mouse after analysis of the organs (140/140 mice) or after microscopic analysis of different tissues (brain, lungs, kidneys, BM, liver and gut) (140/140 mice).
Quantitative PCR
Total mRNA was isolated with the RNA minikit (Qiagen, Courtaboeuf, France 
Statistical analysis
All statistics were determined with R Software 3. 
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